

# Yoshiteru Takekita

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8346965/publications.pdf>

Version: 2024-02-01

39  
papers

825  
citations

567144

15  
h-index

501076

28  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1237  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients. <i>Neuropsychobiology</i> , 2006, 53, 186-195.	0.9	143
2	ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 398-404.	2.5	126
3	Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 115-123.	1.1	89
4	Differences in quantitative EEG between frontotemporal dementia and Alzheimer's disease as revealed by LORETA. <i>Clinical Neurophysiology</i> , 2011, 122, 1718-1725.	0.7	69
5	The Alpha 2A-Adrenergic Receptor Gene Polymorphism Modifies Antidepressant Responses to Milnacipran. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 518-524.	0.7	30
6	Antidepressant response and intolerance to SSRI is not influenced by G-protein $\beta 3$ subunit gene C825T polymorphism in Japanese major depressive patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1041-1044.	2.5	29
7	Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2019, 209, 50-57.	1.1	27
8	HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv125.	1.0	26
9	Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. <i>European Neuropsychopharmacology</i> , 2009, 19, 718-725.	0.3	24
10	Remifentanyl in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 703-717.	1.8	24
11	HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 220-227.	0.7	22
12	The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. <i>Neuropsychobiology</i> , 2016, 73, 35-42.	0.9	21
13	Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. <i>Translational Psychiatry</i> , 2015, 5, e513-e513.	2.4	20
14	Therapeutic Response to Paroxetine in Major Depressive Disorder Predicted by DNA Methylation. <i>Neuropsychobiology</i> , 2017, 75, 81-88.	0.9	19
15	Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. <i>Journal of Psychiatric Research</i> , 2017, 89, 97-104.	1.5	17
16	Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. <i>BMC Psychiatry</i> , 2016, 16, 172.	1.1	16
17	A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 40, 110-114.	2.5	13
18	5-HTTLPR rs25531A > G Differentially Influence Paroxetine and Fluvoxamine Antidepressant Efficacy. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 131-132.	0.7	12

#	ARTICLE	IF	CITATIONS
19	Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 27-31.	0.7	11
20	Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine: a case report. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 433-434.	1.3	9
21	Delirium Associated with Paroxetine in an Elderly Depressive Patient: A Case Report. <i>Pharmacopsychiatry</i> , 2007, 40, 199-200.	1.7	8
22	Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. <i>Neuropsychobiology</i> , 2015, 72, 118-125.	0.9	8
23	Case of adult-onset type I citrullinemia treated as schizophrenia for a long time. <i>Psychiatry and Clinical Neurosciences</i> , 2015, 69, 306-307.	1.0	8
24	Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3873.	1.8	8
25	Neuropsychological Evaluation and Cerebral Blood Flow Effects of Apolipoprotein E4 in Alzheimer's Disease Patients after One Year of Treatment: An Exploratory Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 414-423.	0.6	7
26	Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 785-793.	1.3	6
27	Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 579-588.	1.8	5
28	Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms. <i>Human Psychopharmacology</i> , 2021, 36, e2804.	0.7	5
29	Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3 $\beta$ Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder. <i>Neuropsychobiology</i> , 2019, 78, 136-144.	0.9	4
30	Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks. <i>Journal of Affective Disorders</i> , 2022, 314, 27-33.	2.0	4
31	A series of case reports on abnormal sensation on eye movement associated with paroxetine discontinuation. <i>International Clinical Psychopharmacology</i> , 2006, 21, A29-A30.	0.9	3
32	Olfactory reference syndrome treated by blonanserin augmentation. <i>Psychiatry and Clinical Neurosciences</i> , 2011, 65, 203-204.	1.0	3
33	Sevoflurane in electroconvulsive therapy: A systematic review and meta-analysis of randomised trials. <i>Journal of Psychiatric Research</i> , 2021, 141, 16-25.	1.5	3
34	Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder. <i>BJPsych Open</i> , 2018, 4, 454-460.	0.3	2
35	Divergence of dose-response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study. <i>CNS Spectrums</i> , 2022, 27, 369-377.	0.7	2
36	5-HTTLPR rs25531A > G Differentially Influence Paroxetine and Fluvoxamine Antidepressant Efficacy. <i>Journal of Clinical Psychopharmacology</i> , 2012, , 1.	0.7	1

#	ARTICLE	IF	CITATIONS
37	Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?. Evidence-Based Mental Health, 2016, 19, e25-e25.	2.2	0
38	<p>Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database</p>. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2871-2879.	1.0	0
39	Sevoflurane anesthesia in electroconvulsive therapy: a meta-analysis of randomized controlled trials. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-1-90.	0.0	0